Targeting CLPTM1L for treatment and prevention of cancer
US10829548B2 · kind B2 · utility
1Cited by
13References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 28, 2019 |
| Grant date | Nov 10, 2020 |
| Priority date | — |
| Expiry date | Feb 28, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are therapeutic agents having specificity for human CLPTM1L polypeptide, including therapeutic agents comprising one or more CLPTM1L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L protein dysfunction (e.g., pathogenic production, modification, or function).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.